Φορτώνει......
Cost-Effectiveness of Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia and Pneumonia
Ceftazidime-avibactam (CAZ-AVI) may improve outcomes among patients with carbapenem-resistant Enterobacteriaceae (CRE) infections compared to those with conventional therapies. However, CAZ-AVI’s cost-effectiveness is unknown. We used a decision analytic model to estimate the health and economic con...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Antimicrob Agents Chemother |
|---|---|
| Κύριοι συγγραφείς: | , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
American Society for Microbiology
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6879229/ https://ncbi.nlm.nih.gov/pubmed/31548187 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00897-19 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|